BACKGROUND: The role of promoter methylation in the inactivation of E-cadherin (E-cad) in salivary gland adenoid cystic carcinoma (ACC) is unknown. The objective of this study was to determine the role and potential clinical implications of promoter methylation of E-cad in salivary gland ACC. METHODS: The promoter methylation status of E-cad was determined by using methylation-specific polymerase chain reaction (PCR) analysis in 60 primary salivary gland ACC tissues and 3 ACC cell lines. The level of E-cad protein expression was determined by immunohistochemical analysis of each tumor. E-cad protein and messenger RNA (mRNA) expression levels were examined by immunohistochemical analysis and reverse transcriptase-PCR in 3 ACC cell lines. Associations between molecular alterations and patients' clinicopathologic characteristics were analyzed statistically. E-cad mRNA expression was examined in a 5-azacytidine-treated ACC-2 cell line. RESULTS: Promoter methylation of E-cad was detected in 34 of 60 tumors (57%). Of those 34 tumors, 18 tumors (53%) showed no E-cad protein expression, whereas only 5 of the remaining 26 tumors (19%) without E-cad promoter methylation showed no E-cad protein expression (P = .01). Tumors that had E-cad promoter methylation had a significantly higher histologic grade (P = .01) and more perineural invasion (P = .02) compared with tumors that did not have methylation. All 3 ACC cell lines exhibited E-cad promoter methylation and a lack of E-cad mRNA and protein expression, whereas 5-azacytidine restoredE-cad mRNA expression in the ACC-2 cell line. CONCLUSIONS: E-cad frequently is inactivated in salivary gland ACC through promoter methylation, and E-cad promoter methylation may play a role in tumor cell differentiation and perineural invasion. Copyright (c) 2007 American Cancer Society.
BACKGROUND: The role of promoter methylation in the inactivation of E-cadherin (E-cad) in salivary gland adenoid cystic carcinoma (ACC) is unknown. The objective of this study was to determine the role and potential clinical implications of promoter methylation of E-cad in salivary gland ACC. METHODS: The promoter methylation status of E-cad was determined by using methylation-specific polymerase chain reaction (PCR) analysis in 60 primary salivary gland ACC tissues and 3 ACC cell lines. The level of E-cad protein expression was determined by immunohistochemical analysis of each tumor. E-cad protein and messenger RNA (mRNA) expression levels were examined by immunohistochemical analysis and reverse transcriptase-PCR in 3 ACC cell lines. Associations between molecular alterations and patients' clinicopathologic characteristics were analyzed statistically. E-cad mRNA expression was examined in a 5-azacytidine-treated ACC-2 cell line. RESULTS: Promoter methylation of E-cad was detected in 34 of 60 tumors (57%). Of those 34 tumors, 18 tumors (53%) showed no E-cad protein expression, whereas only 5 of the remaining 26 tumors (19%) without E-cad promoter methylation showed no E-cad protein expression (P = .01). Tumors that had E-cad promoter methylation had a significantly higher histologic grade (P = .01) and more perineural invasion (P = .02) compared with tumors that did not have methylation. All 3 ACC cell lines exhibited E-cad promoter methylation and a lack of E-cad mRNA and protein expression, whereas 5-azacytidine restoredE-cad mRNA expression in the ACC-2 cell line. CONCLUSIONS:E-cad frequently is inactivated in salivary gland ACC through promoter methylation, and E-cad promoter methylation may play a role in tumor cell differentiation and perineural invasion. Copyright (c) 2007 American Cancer Society.
Authors: Zaid A Siddiqui; Edward Melian; Anil Sethi; Vikram C Prabhu; Iris Rusu; Bahman Emami; John P Leonetti; Douglas E Anderson Journal: J Neurol Surg B Skull Base Date: 2016-07-18
Authors: Chunbo Shao; Wenyue Sun; Marietta Tan; Chad A Glazer; Sheetal Bhan; Xiaoli Zhong; Carole Fakhry; Rajni Sharma; William H Westra; Mohammad O Hoque; Christopher A Moskaluk; David Sidransky; Joseph A Califano; Patrick K Ha Journal: Clin Cancer Res Date: 2011-05-06 Impact factor: 12.531
Authors: Chunbo Shao; Weiliang Bai; Jacqueline C Junn; Mamoru Uemura; Patrick T Hennessey; David Zaboli; David Sidransky; Joseph A Califano; Patrick K Ha Journal: Oral Oncol Date: 2011-02-15 Impact factor: 5.337
Authors: Megan L Durr; Wojciech K Mydlarz; Chunbo Shao; Marianna L Zahurak; Alice Y Chuang; Mohammad O Hoque; William H Westra; Nanette J Liegeois; Joseph A Califano; David Sidransky; Patrick K Ha Journal: PLoS One Date: 2010-05-26 Impact factor: 3.240
Authors: Marietta Tan; Chunbo Shao; Justin A Bishop; Zhaoyong Feng; Bruce J Trock; William H Westra; Patrick K Ha Journal: Otolaryngol Head Neck Surg Date: 2014-02-03 Impact factor: 3.497
Authors: Valéria Souza Freitas; Jean Nunes Dos Santos; Pedro Paulo de Andrade Santos; Cassiano Francisco Weege Nonaka; Leão Pereira Pinto; Lélia Batista de Souza Journal: Eur Arch Otorhinolaryngol Date: 2018-10-25 Impact factor: 2.503
Authors: W Ding; H Dang; H You; S Steinway; Y Takahashi; H-G Wang; J Liao; B Stiles; R Albert; C B Rountree Journal: Oncogenesis Date: 2012-06-11 Impact factor: 7.485